Advanced searches left 3/3

Peripheral Neuropathy - Europe PMC

Summarized by Plex Scholar
Last Updated: 15 July 2022

* If you want to update the article please login/register

Diabetic corneal neuropathy as a surrogate marker for diabetic peripheral neuropathy.

Diabetic neuropathy is a common microvascular disorder of diabetes mellitus, affecting nerves in all areas of the body, including corneal nerves and peripheral nervous system, contributing to diabetic corneal neuropathy and diabetic peripheral neuropathy, respectively. We'll explore the role of diabetic peripheral neuropathy in determining diabetic peripheral neuropathy, particularly early diabetic peripheral neuropathy; the connection between diabetic corneal neuropathy and diabetic peripheral neuropathy; and the role of diabetic corneal neuropathy in the stratification of diabetic peripheral neuropathy.

Source link: https://europepmc.org/article/MED/35259825


Chemotherapy-induced peripheral neuropathy onset is associated with early risk of depression and anxiety in breast cancer survivors.

In breast cancer survivors, the aim was to look for a connection between chemotherapy-induced peripheral neuropathy onset and increased risk of depression and anxiety. Compared to BrCa+/CIPN+ and BrCa-/CIPN+, the ratio of the prevalence ratios determined if the change in the risk of depression and anxiety from the 12-month baseline period to postindex period I and II was different for BrCa+/CIPN+ and BrCa-/CIPN+. For postindex periods I and II, the RPR for anxiety was markedly higher for BrCa+/CIPN+ relative to BrCa+/CIPN- and BrCa-/CIPN+.

Source link: https://europepmc.org/article/MED/35830192


Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy induced peripheral neuropathy

Pediatric neuropathy is a common dose-limiting neuropathy of chemotherapies with no effective treatment for prevention. In 14 randomized controlled trials, we conducted a meta-analysis of time-to-PN using WGS results in 4,900 European-ancestry patients receiving chemotherapeutic agents. Intron 13 of GRID2 and rs115575220 downstream of SCG2, we found two low frequency variants of PN risk: rs17020773 in intron 13 of GRID2 and rs115575220 downstream of SCG2: Intron 13 of GRID2 and rs1175220 downstream of SCG2. The expression of GPR68 was the highest in mechano-thermo sensitive nociceptors, according to a study of snRNA-seq from human dorsal root ganglia. Inhibition of GPR68 signaling may be a way to minimize PN in cancer patients.

Source link: https://europepmc.org/article/PPR/PPR517882


Efficacy of vitamin and antioxidant supplements for treatment of diabetic peripheral neuropathy: systematic review and meta-analysis of randomized controlled trials.

ABSTRACT The effects of vitamin or antioxidant intake on diabetic peripheral neuropathy in diabetic peripheral neuropathy were not consistent. Vitamin and antioxidant supplements were included in All RCTs of DPN treatments. Vitamin and antioxidant supplements had a significant increase in sensory nerve conduction velocity of the sural nerve, according to three high-quality studies. With the random-effect model, seven research found that these supplements may have an effect on motor nerve conduction velocity in DPN patients. These supplements may have had an effect on MNCV of the median nerve in four studies, according to a study by the fixed-effect model. However, ten studies have shown that vitamin and antioxidant supplements have not reduced glycosylated hemoglobin in a diabetic study. Vitamin and antioxidant supplements may help nerves, especially median, sural, and peroneal nerve nerves of patients with DPN, improve nerve conduction velocity. However, these drugs haven't reduced HbA1c in DPN patients.

Source link: https://europepmc.org/article/MED/35816410


Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.

Background The use of oxaliplatin in digestive tract cancers may cause severe peripheral neuropathy in patients and survivors, as well as patients and survivors. It will be the first clinical trial to determine the efficacy and safety of donepezil for the management of OIPN. According to QLQ-CIPN20's sensory score, at least 6 months after the end of an oxaliplatin-based chemotherapy will be included, adult cancer survivors with OIPN who report sensory neuropathy. Over 16 weeks of therapy, eighty patients will be randomly selected to receive either donepezil or placebo. The other secondary endpoints would be tolerance to donepezil, the severity, and characteristics of OIPN in each arm before and after diagnosis, related-comorbidities, and quality of life. Discussion This research will help you establish a phase 3 randomized and placebo-controlled clinical trial to determine the therapeutic interest of donepezil in treating OIPN in the event of positive results.

Source link: https://europepmc.org/article/MED/35799138


Anti-neuropathic effect of 7,3'-dihydroxyflavone in paclitaxel induced peripheral neuropathy in mice involving GABA A , K ATP channel and adenosine receptors.

The most common dose-limiting adverse reaction observed in patients during and after treatment of malignancies is peripheral neuropathy induced by chemotherapeutic agents is peripheral neuropathy. The current research intends to investigate 7,3'-dihydroxyflavone's anti-neuropathic effect against paclitaxel-induced peripheral neuropathy in mice by using behavioural methods such as mechanical allodynia, cold allodynia, and thermal hyperalgesia. Dialogue dehydrogenol-induced neuropathy is a complex and variablely reduced the paw withdrawal response score in both mechanical and cold allodynia, as well as increasing the tail flick reaction time in thermal hyperalgesia due to paclitaxel-induced neuropathy.

Source link: https://europepmc.org/article/MED/35809719


Clinical Implications of Diabetic Peripheral Neuropathy in Primary Infrapopliteal Angioplasty Approach for Neuro-Ischemic Foot Wounds.

Background To determine the clinical effects of diabetic peripheral neuropathy in patients with chronic leg-threatening ischemia treated by primary infrapoplitean angioplasty for neuro-ischemic Rutherford 5, foot wounds. In all prospective diabetic patients, an Inferior limb vibration assessment threshold diagnostic was used for comparing and scoring detectable DPN. Primary infrapopliteal angioplasty succeeded in 89% cases in group 1, 82% in group 2, and 68% of limbs in group 3. The comparison of primary patency, tissue repair, and leg salvage showed a lot, but there was no evidence for group 1 vs. 2 vs. 2 vs. 3 of primary patency, tissue repair, and leg salvage was encouraging, but no statistical data was available for group 1 vs. 2 vs. 2. Conclusions: The presence of strong DPN could jeopardize the results of infrapopliteal angioplasty in terms of patency, tissue cicatrization, and leg preservation, but not so much emphasis on longevity of these patients.

Source link: https://europepmc.org/article/MED/35786131


Paclitaxel Treatment Effects on Neurofilament Light Chain (NF-L), a Possible Biomarker of Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Methods Female breast cancer patients at two hospitals receiving weekly or biweekly paclitaxel chemotherapy for 3-4 cycles per two weeks. Complete blood draws every two weeks. On day 1 of each pactaxel cycle and within 30 days of the final therapy to determine chemotherapy-induced peripheral neuropathy, patients underwent clinical neuropathy grading and a symptom questionnaire with a neuropathy specific subscale. Given the widespread use of CIPN and the effects of CIPN on pain, quality of life, and dose reductions, CIPN biomarker qualification is a critical area of survivorship study. Future research with a larger sample, longer follow-up, and objective neuropathic measures may show whether NF-L can be used to distinguish women who will experience CIPN during taxane treatment versus those who will not.

Source link: https://europepmc.org/article/MED/35775215


Shaoyao Gancao Decoction Ameliorates Paclitaxel-Induced Peripheral Neuropathy via Suppressing TRPV1 and TLR4 Signaling Expression in Rats.

Purpose Paclitaxel-induced peripheral neuropathy is quickly becoming one of the most common adverse effects in cancer therapy and neuroinflammation in the nervous system, and can lead to neuroinflammation in the nervous system. Methods First, network pharmacology, was used to determine the role of the transient receptor potential vanilloid type 1 protein in treating SGD in PIPN patients with SGD. In rat PIPN models, the effects of SGD therapy on mechanical allodynia and thermal hypergestia were explored later. Paclitaxel activates toll-like receptor 4 in the sensitization of TRPV1 mechanistically based on bioinformatics findings and current literature. Conclusion - Our results, in turn, show that SGD enhances PIPN by inhibiting the overexpression of TLR4-MyD88 Signaling and TRPV1, which also highlights the use of SGD as a potential alternative therapy for PIPN.

Source link: https://europepmc.org/article/MED/35795847


Remote Research: Resources, Intervention Needs, and Methods in People with Diabetes and Peripheral Neuropathy.

Background Staying-at-home orders as a result of the SARS-CoV-2 pandemic were particularly important for older adults with type 2 diabetes who were at risk for severe COVID-19 complications. The purpose of this study is to determine resource availability, future telehealth needs, and the ability to implement standard research and clinical tools of glycemic regulation, physical fitness, fitness tracking, and quality of life outcomes in a telehealth environment. From a longitudinal study, twenty-one participants with type 2 diabetes and peripheral neuropathy were recruited. Twelve participants used computers; nine out of ten used cellphones for study completion; nine used phones for research completion. Twenty people expressed interest in participating in future telehealth research relating to balance, exercise, and diabetes prevention. To complete a long-term telehealth intervention, older adults with type 2 diabetes and peripheral neuropathy will need medical and personal assistance. http://clinicaltrials. gov/Matesal Phalangeal Joint Deformity Progression-R01 is a registered trial at www. clinicaltrials. gov/'s curriculum.

Source link: https://europepmc.org/article/MED/35770988

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions